CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state‐of‐the art production facilities.
Chief Executive Officer & Chief Financial Officer
Mr. Dowling was appointed as Chief Executive Officer of the Company in May 2018. Prior to his appointment as CEO, Mr. Dowling held the position of CFO with the Company since 2014D. Prior to 2014, Mr. Dowling held numerous senior positions including President and Chief Financial Officer of MediVas, LLC, a biotechnology company focused on drug formulation and delivery from 2005 to 2013 where he led day-to-day operations, drug research and development, product development and commercialization and strategic alliance building including license agreements with Pfizer, Merck, Wyeth, DSM, Guidant and Boston Scientific. Mr. Dowling also served as a Managing Director at Citigroup, a global financial services firm, and earlier in his career served various operating, finance and accounting roles in both public accounting and in the banking industry. Mr. Dowling graduated from University of California, Los Angeles in Economics and is a certified public accountant.
President, Co-Founder & Chief Operating Officer
Mr. Mona III cofounded CV Sciences and has been instrumental in developing the worldwide supply chain for hemp products. Mr. Mona’s expertise in hemp farming, processing, testing and product development has directly led to the Company’s successful consumer products division. Mr. Mona III graduated from the University of San Diego in Business Administration.
Director of CV Sciences
Mr. Gary R. Sligar served as Managing Principal, President at Trecap Partners, LLC. Mr. Sligar joined Equitable Real Estate in 1986 with responsibility for New York Region asset management operations. Mr. Sligar was the Executive Vice President responsible for the New York office asset management operations for Equitable Real Estate from 1986 to 1989. Mr. Sligar’s career spans 35 years in the commercial real estate industry including appraisal, commercial mortgage, property/asset management, leasing, construction and development. He serves as a Director of the Real Estate Board of New York, Building Owners and Managers Association, and NAIOP. He has served as a Director of CV Sciences, Inc. since June 2, 2016. He received his Bachelor Degree from Tulsa University and completed his graduate study at the University of Houston.
Director of CV Sciences
Mr. James A. McNulty, CPA, has served as a Director of CV Sciences, Inc. since January 1, 2016. He is CEO of MYMD Pharmaceuticals, Inc. (development stage pharmaceutical company), and is Chief Financial Officer for Hopkins Capital Group, an affiliation of limited liability companies which engage in venture activities primarily in development of pharmaceuticals. He serves as Chief Financial Officer of Repurposed Therapeutics, Inc., DBA Defender Pharmaceuticals, Inc. Mr. McNulty was Chief Financial Officer of Biodelivery Sciences International, Inc. (NASDAQ: BDSI) from 2000 until his retirement from BDSI in December 2014.